When anlotinib is used in conjunction with another EGFR-TKI and immune checkpoint inhibitor, sintilimab, anlotinib also shows encouraging anticancer effects in the first-line scenario for advanced NSCLC [58,59]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.